Premium
ABO blood group alleles and prostate cancer risk: Results from the breast and prostate cancer cohort consortium (BPC3)
Author(s) -
Markt Sarah C.,
Shui Irene M.,
Unger Robert H.,
Urun Yuksel,
Berg Christine D.,
Black Amanda,
Brennan Paul,
BuenodeMesquita H. Bas,
Gapstur Susan M.,
Giovannucci Edward,
Haiman Christopher,
Henderson Brian,
Hoover Robert N.,
Hunter David J.,
Key Timothy J.,
Khaw KayTee,
Canzian Federico,
Larranga Nerea,
Le Marchand Loic,
Ma Jing,
Naccarati Alessio,
Siddiq Afshan,
Stampfer Meir J.,
Stattin Par,
Stevens Victoria L.,
Stram Daniel O.,
Tjønneland Anne,
Travis Ruth C.,
Trichopoulos Dimitrios,
Ziegler Regina G.,
Lindstrom Sara,
Kraft Peter,
Mucci Lorelei A.,
Choueiri Toni K.,
Wilson Kathryn M.
Publication year - 2015
Publication title -
the prostate
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.295
H-Index - 123
eISSN - 1097-0045
pISSN - 0270-4137
DOI - 10.1002/pros.23035
Subject(s) - abo blood group system , prostate cancer , medicine , oncology , prostate , odds ratio , cancer , blood type (non human) , breast cancer , cohort , gynecology
Background ABO blood group has been associated with risk of cancers of the pancreas, stomach, ovary, kidney, and skin, but has not been evaluated in relation to risk of aggressive prostate cancer. Methods We used three single nucleotide polymorphisms (SNPs) (rs8176746, rs505922, and rs8176704) to determine ABO genotype in 2,774 aggressive prostate cancer cases and 4,443 controls from the Breast and Prostate Cancer Cohort Consortium (BPC3). Unconditional logistic regression was used to calculate age and study‐adjusted odds ratios and 95% confidence intervals for the association between blood type, genotype, and risk of aggressive prostate cancer (Gleason score ≥8 or locally advanced/metastatic disease (stage T3/T4/N1/M1). Results We found no association between ABO blood type and risk of aggressive prostate cancer (Type A: OR = 0.97, 95%CI = 0.87–1.08; Type B: OR = 0.92, 95%CI =n0.77–1.09; Type AB: OR = 1.25, 95%CI = 0.98–1.59, compared to Type O, respectively). Similarly, there was no association between “dose” of A or B alleles and aggressive prostate cancer risk. Conclusions ABO blood type was not associated with risk of aggressive prostate cancer. Prostate 75:1677–1681, 2015 . © 2015 Wiley Periodicals, Inc.